The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing

Toxicology Letters

Volumn 194, Issue 3, 2010, Pages 102-107

  Haglund, Caroline ^a   Åleskog, Anna ^a   Håkansson, Lena Douhan ^a   Höglund, Martin ^a   Jacobsson, Stefan ^b   Larsson, Rolf ^a   Lindhagen, Elin ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CFU GM; FMCA; Hematotoxicity; High throughput screening

Indexed keywords

ACICLOVIR; BORTEZOMIB; BUSULFAN; CARBOPLATIN; CD34 ANTIGEN; CHLORAMPHENICOL; CHLORPROMAZINE; CISPLATIN; CLOZAPINE; CYTARABINE; CYTOKINE; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYDROXYUREA; IMATINIB; LOMUSTINE; MELPHALAN; PACLITAXEL; SORAFENIB; SUNITINIB; TIOGUANINE;

ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CD34 SELECTION; CELL CULTURE; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CELL VIABILITY; CLONOGENIC ASSAY; COLONY FORMING UNIT GM; CONTROLLED STUDY; CYTOTOXICITY TEST; GRANULOCYTE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIQUID CULTURE; MACROPHAGE; MICROFLUOROMETRY; PRIORITY JOURNAL; THAWING; UMBILICAL CORD BLOOD;

ANTIGENS, CD34; CELL CULTURE TECHNIQUES; DRUG EVALUATION, PRECLINICAL; FETAL BLOOD; FLOW CYTOMETRY; FLUOROMETRY; GRANULOCYTE-MACROPHAGE PROGENITOR CELLS; HUMANS; INHIBITORY CONCENTRATION 50; REPRODUCIBILITY OF RESULTS; STEM CELLS;

EID: 77950859861     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.02.006     Document Type: Article

References (26)

1. Bradley T.R., Metcalf D. The growth of mouse bone marrow cells in vitro. Aust. J. Exp. Biol. Med. Sci. 1966, 44:287-299.
2. Cerrato L., Valeri A., Bueren J.A., Albella B. In vitro sensitivity of granulo-monocytic progenitors as a new toxicological cell system and endpoint in the ACuteTox Project. Toxicol. Appl. Pharmacol. 2009, 238:111-119.
3. Dal Negro G., Vandin L., Bonato M., Sciuscio D. Toward refinement of the colony-forming unit-granulocyte/macrophage clonogenic assay: inclusion of a metabolic system. Toxicol. In Vitro 2006, 20:743-749.
4. Ferlini C., Distefano M., Pierelli L., Bonanno G., Fattorossi A., Battaglia A., Mancuso S., Scambia G. A new method to evaluate in vitro myelotoxicity of antitumour agents in the first steps of drug development. Pharmacol. Toxicol. 2001, 89:231-236.
5. Ghielmini M., Colli E., Bosshard G., Pennella G., Geroni C., Torri V., D'Incalci M., Cavalli F., Sessa C. Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites. Cancer Chemother. Pharmacol. 1998, 42:235-240.
6. Gomez S.G., Faircloth G., Lopez-Lazaro L., Jimeno J., Bueren J.A., Albella B. In vitro hematotoxicity of Aplidine on human bone marrow and cord blood progenitor cells. Toxicol. In Vitro 2001, 15:347-350.
7. Greenwalt D.E., Szabo J., Manchel I. High throughput cell-based assay of hematopoietic progenitor differentiation. J. Biomol. Screen. 2001, 6:383-392.
8. Gribaldo L. Haematotoxicology: scientific basis and regulatory aspects. Altern. Lab. Anim. 2002, 30(Suppl. 2):111-113.
9. Gribaldo L., Casati S., Castoldi A.F., Pessina A. Comparison of in vitro drug-sensitivity of human granulocyte-macrophage progenitors from two different origins: umbilical cord blood and bone marrow. Exp. Hematol. 1999, 27:1593-1598.
10. Hassan S.B., Haglund C., Aleskog A., Larsson R., Lindhagen E. Primary lymphocytes as predictors for species differences in cytotoxic drug sensitivity. Toxicol. In Vitro 2007, 21:1174-1181.
11. Larsson R., Kristensen J., Sandberg C., Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer 1992, 50:177-185.
12. Leglise M.C., Darodes de Tailly P., Vignot J.L., Le Bot M.A., Le Roux A.M., Riche C. A cellular model for drug interactions on hematopoiesis: the use of human umbilical cord blood progenitors as a model for the study of drug-related myelosuppression of normal hematopoiesis. Cell Biol. Toxicol. 1996, 12:39-53.
13. Lindhagen E., Nygren P., Larsson R. The fluorometric microculture cytotoxicity assay. Nat. Protoc. 2008, 3:1364-1369.
14. Malerba I., Castoldi A.F., Parent-Massin D., Gribaldo L. In vitro myelotoxicity of propanil and 3,4-dichloroaniline on murine and human CFU-E/BFU-E progenitors. Toxicol. Sci. 2002, 69:433-438.
15. Masubuchi N., May R.D., Atsumi R. A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay. Clin. Cancer Res. 2004, 10:6722-6731.
16. Olaharski A.J., Uppal H., Cooper M., Platz S., Zabka T.S., Kolaja K.L. In vitro to in vivo concordance of a high throughput assay of bone marrow toxicity across a diverse set of drug candidates. Toxicol. Lett. 2009, 188:98-103.
17. Pessina A., Albella B., Bayo M., Bueren J., Brantom P., Casati S., Croera C., Gagliardi G., Foti P., Parchment R., Parent-Massin D., Schoeters G., Sibiril Y., Van Den Heuvel R., Gribaldo L. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol. Sci. 2003, 75:355-367.
18. Pessina A., Albella B., Bueren J., Brantom P., Casati S., Gribaldo L., Croera C., Gagliardi G., Foti P., Parchment R., Parent-Massin D., Sibiril Y., Van Den Heuvel R. Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicol. In Vitro 2001, 15:729-740.
19. Pessina A., Malerba I., Gribaldo L. Hematotoxicity testing by cell clonogenic assay in drug development and preclinical trials. Curr. Pharm. Des. 2005, 11:1055-1065.
20. Pessina A., Parent-Massin D., Albella B., Van Den Heuvel R., Casati S., Croera C., Malerba I., Sibiril Y., Gomez S., de Smedt A., Gribaldo L. Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs. Toxicol. In Vitro 2009, 23:194-200.
21. Reems J.A., Hall K.M., Gebru L.H., Taber G., Rich I.N. Development of a novel assay to evaluate the functional potential of umbilical cord blood progenitors. Transfusion (Paris) 2008, 48:620-628.
22. Rich I.N., Hall K.M. Validation and development of a predictive paradigm for hemotoxicology using a multifunctional bioluminescence colony-forming proliferation assay. Toxicol. Sci. 2005, 87:427-441.
23. Rickardson L., Fryknas M., Dhar S., Lovborg H., Gullbo J., Rydaker M., Nygren P., Gustafsson M.G., Larsson R., Isaksson A. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br. J. Cancer 2005, 93:483-492.
24. Servida F., Soligo D., Delia D., Henderson C., Brancolini C., Lombardi L., Deliliers G.L. Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia 2005, 19:2324-2331.
25. Su W.C., Chang S.L., Chen T.Y., Chen J.S., Tsao C.J. Comparison of in vitro growth-inhibitory activity of carboplatin and cisplatin on leukemic cells and hematopoietic progenitors: the myelosuppressive activity of carboplatin may be greater than its antileukemic effect. Jpn. J. Clin. Oncol. 2000, 30:562-567.
26. Volpe D.A., Warren M.K. Myeloid clonogenic assays for comparison of the in vitro toxicity of alkylating agents. Toxicol. In Vitro 2003, 17:271-277.